{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:21Z","timestamp":1792800261641,"version":"4.5.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81470813"],"award-info":[{"award-number":["81470813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0172846","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T18:09:30Z","timestamp":1489514970000},"page":"e0172846","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":76,"title":["Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"12","author":[{"given":"Yongping","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"ref1","article-title":"Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV","author":"DA Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref2","article-title":"Bowel Disorders","author":"F Mearin","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00535-014-1017-0","article-title":"Evidence-based clinical practice guidelines for irritable bowel syndrome","volume":"50","author":"S Fukudo","year":"2015","journal-title":"J Gastroenterol"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"AC Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2036.2010.04395.x","article-title":"Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging","volume":"32","author":"L Marciani","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2006.02858.x","article-title":"Review article: intestinal serotonin signaling in irritable bowel syndrome","volume":"23","author":"GM Mawe","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/IJGM.S93698","article-title":"Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome","volume":"9","author":"BE Lacy","year":"2016","journal-title":"Int J Gen Med"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2036.2012.05208.x","article-title":"Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS","volume":"36","author":"F Cremonini","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/j.gastro.2015.10.047","article-title":"Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women","volume":"150","author":"S Fukudo","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00535-016-1165-5","article-title":"Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study","volume":"51","author":"S Fukudo","year":"2016","journal-title":"J Gastroenterol"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2036.2012.05208.x","article-title":"Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS","volume":"36","author":"F Cremonini","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"K Garsed","year":"2014","journal-title":"Gut"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coph.2011.02.005","article-title":"Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome","volume":"11","author":"RC Spiller","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/gutjnl-2014-307551","article-title":"Ondansetron and irritable bowel syndrome","volume":"64","author":"P Luthra","year":"2015","journal-title":"Gut"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"V Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","first-page":"32124","article-title":"Food and Drug Administration [docket no. FDA\u20132012\u2013D\u20130146]: guidance for industry on irritable bowel syndrome\u2014clinical evaluation of drugs for treatment: availability","volume":"77","author":"L Kux","year":"2012","journal-title":"Fed Register"},{"issue":"7414","key":"ref17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/0962280210392008","article-title":"Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: A simulation study","volume":"21","author":"E Kontopantelis","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"ref19","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated march] the cochrane collaboration; 2011. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cochrane-handbook.org\" xlink:type=\"simple\">www.cochrane-handbook.org<\/ext-link>."},{"issue":"4 SUPPL. 1","key":"ref20","first-page":"S659","article-title":"Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II trial","volume":"148","author":"S Fukudo","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cgh.2013.11.024","article-title":"Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea","volume":"12","author":"S Fukudo","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2982.2011.01771.x","article-title":"Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine","volume":"23","author":"KJ Lee","year":"2011","journal-title":"Neurogastroenterol Motil"},{"issue":"3\u20134","key":"ref23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000150632","article-title":"A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome","volume":"77","author":"K Matsueda","year":"2008","journal-title":"Digestion"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/00365520802240255","article-title":"A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome","volume":"43","author":"K Matsueda","year":"2008","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"R Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"L Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1542-3565(04)00284-8","article-title":"Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials","volume":"2","author":"AJ Lembo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome","volume":"99","author":"WD Chey","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"ref29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"M Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"T Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","article-title":"A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome","volume":"14","author":"KD Bardhan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"9209","key":"ref32","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial","volume":"355","author":"M Camilleri","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"M Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.1999.00678.x","article-title":"Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients","volume":"13","author":"RH Jones","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2036.1996.30172000.x","article-title":"Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?","volume":"10","author":"DG Maxton","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"ref36","first-page":"A42","article-title":"Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study","volume":"126","author":"M Bradette","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"ref37","first-page":"A600","article-title":"Interruption of daily activities in cilansetron-treated patients with irritable bowel syndrome with diarrhea-predominance (IBS-D): results from a 16-week, placebo-controlled, rerandomization trial","volume":"130","author":"CF Francisconi","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"ref38","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.14309\/00000434-200410001-00846","article-title":"Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 3 month US study","volume":"99","author":"P Miner","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cgh.2013.12.025","article-title":"Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?","volume":"12","author":"M Grover","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/j.1572-0241.2001.04138.x","article-title":"Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome","volume":"96","author":"BE Viramontes","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2036.2004.02031.x","article-title":"Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors","volume":"20","author":"KM Koch","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1046\/j.1365-2036.2002.01287.x","article-title":"The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients","volume":"16","author":"EA Mayer","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"ref43","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0016-5085(03)00400-1","article-title":"Sex-related differences in IBS patients: central processing of visceral stimuli","volume":"124","author":"BD Naliboff","year":"2003","journal-title":"Gastroenterology"},{"issue":"18","key":"ref44","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1517\/14656566.2015.1101449","article-title":"Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome","volume":"16","author":"J Nee","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CEG.S32721","article-title":"Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome","volume":"6","author":"T Chiba","year":"2013","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/cn300166c","article-title":"Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D","volume":"4","author":"NA Moore","year":"2013","journal-title":"ACS Chem Neurosci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0172846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T23:50:34Z","timestamp":1719100234000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0172846"}},"subtitle":[],"editor":[{"given":"John","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0172846","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]}}}